Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical, molecular, and histological characteristics of severely necrotic and fatal mpox in HIV-infected patients.
Rajme-López S, Corral-Herrera EA, Tello-Mercado AC, Tepo-Ponce KM, Pérez-Meléndez RE, Rosales-Sotomayor Á, Figueroa-Ramos G, López-López K, Domínguez-Cherit JG, San-Martín-Morante O, Saeb-Lima M, Gamboa-Domínguez A, Ponce-de-León A, Crabtree-Ramírez B, Ramos-Cervantes P, Ruíz-Palacios GM. Rajme-López S, et al. Among authors: ruiz palacios gm. AIDS Res Ther. 2023 Nov 27;20(1):85. doi: 10.1186/s12981-023-00580-6. AIDS Res Ther. 2023. PMID: 38012656 Free PMC article.
Predictors of Poor Outcomes in Young Non-Comorbid Patients with COVID-19.
Martínez-Guerra BA, Medrano-Borromeo C, González-Lara MF, Román-Montes CM, Tamez-Torres KM, Rajme-López S, Salgado-Guízar KD, Juárez-Menéndez NA, Ramos-Cervantes P, Ruiz-Palacios GM, Ponce-de-León A, Sifuentes-Osornio J. Martínez-Guerra BA, et al. Rev Invest Clin. 2022;74(5):268-275. doi: 10.24875/RIC.22000162. Rev Invest Clin. 2022. PMID: 36328004 Free article.
Early Outpatient Treatment With Remdesivir in Patients at High Risk for Severe COVID-19: A Prospective Cohort Study.
Rajme-López S, Martinez-Guerra BA, Zalapa-Soto J, Román-Montes CM, Tamez-Torres KM, González-Lara MF, Hernandez-Gilosul T, Kershenobich-Stalnikowitz D, Sifuentes-Osornio J, Ponce-de-León A, Ruíz-Palacios GM. Rajme-López S, et al. Open Forum Infect Dis. 2022 Oct 6;9(10):ofac502. doi: 10.1093/ofid/ofac502. eCollection 2022 Oct. Open Forum Infect Dis. 2022. PMID: 36285176 Free PMC article.
Etiology, clinical characteristics, and risk factors associated with severe influenza-like illnesses in Mexican adults.
Guerra-de-Blas PDC, Ortega-Villa AM, Ortiz-Hernández AA, Ramírez-Venegas A, Moreno-Espinosa S, Llamosas-Gallardo B, Pérez-Patrigeon S, Hunsberger S, Magaña M, Valdez-Vázquez R, Freimanis L, Galán-Herrera JF, Guerrero-Almeida ML, Powers JH 3rd, Ruiz-Palacios GM, Beigel J, Galindo-Fraga A; Mexican Emerging Infectious Diseases Clinical Research Networka. Guerra-de-Blas PDC, et al. IJID Reg. 2023 Feb 1;6:152-158. doi: 10.1016/j.ijregi.2023.01.012. eCollection 2023 Mar. IJID Reg. 2023. PMID: 36865993 Free PMC article.
International clinical research networks - a collaborative approach for pandemic preparedness and response: The case of The Mexican Emerging Infectious Disease Clinical Research Network (LaRed).
Ruiz-Palacios GM, Regalado-Pineda J, Montenegro-Liendo A, Guerra-de-Blas PDC, Smolskis M, Lane HC; Mexican Emerging Infectious Disease Clinical Research Network (LaRed). Ruiz-Palacios GM, et al. J Glob Health. 2023 Jul 14;13:03031. doi: 10.7189/jogh.13.03031. J Glob Health. 2023. PMID: 37441774 Free PMC article. No abstract available.
Guillain-Barré syndrome outbreak in Tapachula temporally associated with the Zika virus introduction in Southern Mexico.
Rodríguez de la Rosa RP, Cano-Torres JO, Rosales S, Kleinert AP, Gómez A, George F, George J, Piedad García M, Nájera-Cancino G, Guerra-de-Blas PDC, Belaunzarán-Zamudio PF, Beigel J, Ruiz-Palacios GM; Mexican Emerging Infectious Diseases Clinical Research Network. Rodríguez de la Rosa RP, et al. Epidemiol Infect. 2022 Oct 19;150:e181. doi: 10.1017/S0950268822001625. Epidemiol Infect. 2022. PMID: 36384981 Free PMC article.
SARS-CoV-2 RNA and nucleocapsid antigen are blood biomarkers associated with severe disease outcomes that improve in response to remdesivir.
Singh K, Rubenstein K, Callier V, Shaw-Saliba K, Rupert A, Dewar R, Laverdure S, Highbarger H, Lallemand P, Huang ML, Jerome KR, Sampoleo R, Mills MG, Greninger AL, Juneja K, Porter D, Benson CA, Dempsey W, El Sahly HM, Focht C, Jilg N, Paules CI, Rapaka RR, Uyeki TM, Lane HC, Beigel J, Dodd LE; Adaptive COVID-19 Treatment Trial (ACTT-1) Study Group Members. Singh K, et al. J Infect Dis. 2024 Apr 24:jiae198. doi: 10.1093/infdis/jiae198. Online ahead of print. J Infect Dis. 2024. PMID: 38657001
Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study.
Rajme-López S, Martinez-Guerra BA, Román-Montes CM, Tamez-Torres KM, Tello-Mercado AC, Tepo-Ponce KM, Segura-Ortíz Z, López-Aguirre A, Gutiérrez-Mazariegos ODR, Lazcano-Delgadillo O, Nares-López R, González-Lara MF, Kershenobich-Stalnikowitz D, Sifuentes-Osornio J, Ponce-de-León A, Ruíz-Palacios GM. Rajme-López S, et al. Among authors: ruiz palacios gm. Ther Adv Infect Dis. 2024 Mar 26;11:20499361241236582. doi: 10.1177/20499361241236582. eCollection 2024 Jan-Dec. Ther Adv Infect Dis. 2024. PMID: 38545451 Free PMC article.
Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials.
Siempos II, Kalil AC, Belhadi D, Veiga VC, Cavalcanti AB, Branch-Elliman W, Papoutsi E, Gkirgkiris K, Xixi NA, Kotanidou A, Hermine O, Porcher R, Mariette X; CORIMUNO-19 Collaborative Group; DisCoVeRy Study Group; ACTT-2 Study Group; ACTT-3 Study Group. Siempos II, et al. EClinicalMedicine. 2024 Feb 9;69:102472. doi: 10.1016/j.eclinm.2024.102472. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38361992 Free PMC article.
151 results